|
1.
|
Gregory PA, Bracken CP, Bert AG and
Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal
transition. Cell Cycle. 7:3112–3118. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Puhr M, Hoefer J, Schafer G, et al:
Epithelial-to-mesenchymal transition leads to docetaxel resistance
in prostate cancer and is mediated by reduced expression of
miR-200c and miR-205. Am J Pathol. 181:2188–2201. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Sempere LF, Christensen M, Silahtaroglu A,
et al: Altered MicroRNA expression confined to specific epithelial
cell subpopulations in breast cancer. Cancer Res. 67:11612–11620.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Childs G, Fazzari M, Kung G, et al:
Low-level expression of microRNAs let-7d and miR-205 are prognostic
markers of head and neck squamous cell carcinoma. Am J Pathol.
174:736–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Wiklund ED, Bramsen JB, Hulf T, et al:
Coordinated epigenetic repression of the miR-200 family and miR-205
in invasive bladder cancer. Int J Cancer. 128:1327–1334. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Coppola V, De Maria R and Bonci D:
MicroRNAs and prostate cancer. Endocr Relat Cancer. 17:F1–F17.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Porkka KP, Pfeiffer MJ, Waltering KK,
Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression
profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Schaefer A, Jung M, Mollenkopf HJ, et al:
Diagnostic and prognostic implications of microRNA profiling in
prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.PubMed/NCBI
|
|
9.
|
Chung TK, Cheung TH, Huen NY, et al:
Dysregulated microRNAs and their predicted targets associated with
endometrioid endometrial adenocarcinoma in Hong Kong women. Int J
Cancer. 124:1358–1365. 2009. View Article : Google Scholar
|
|
10.
|
Karaayvaz M, Zhang C, Liang S, Shroyer KR
and Ju J: Prognostic significance of miR-205 in endometrial cancer.
PLoS One. 7:e351582012. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Matsushima K, Isomoto H, Yamaguchi N, et
al: MiRNA-205 modulates cellular invasion and migration via
regulating zinc finger E-box binding homeobox 2 expression in
esophageal squamous cell carcinoma cells. J Transl Med. 9:302011.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Markou A, Tsaroucha EG, Kaklamanis L,
Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of
mature microRNA-21 and microRNA-205 overexpression in non-small
cell lung cancer by quantitative real-time RT-PCR. Clin Chem.
54:1696–1704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Wu H, Zhu S and Mo YY: Suppression of cell
growth and invasion by miR-205 in breast cancer. Cell Res.
19:439–448. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Dar AA, Majid S, de Semir D, Nosrati M,
Bezrookove V and Kashani-Sabet M: miRNA-205 suppresses melanoma
cell proliferation and induces senescence via regulation of E2F1
protein. J Biol Chem. 286:16606–16614. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Piovan C, Palmieri D, Di Leva G, et al:
Oncosuppressive role of p53-induced miR-205 in triple negative
breast cancer. Mol Oncol. 6:458–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Alla V, Kowtharapu BS, Engelmann D, et al:
E2F1 confers anticancer drug resistance by targeting ABC
transporter family members and Bcl-2 via the p73/DNp73-miR-205
circuitry. Cell Cycle. 11:3067–3078. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Gandellini P, Profumo V, Casamichele A, et
al: miR-205 regulates basement membrane deposition in human
prostate: implications for cancer development. Cell Death Differ.
19:1750–1760. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Tucci P, Agostini M, Grespi F, et al: Loss
of p63 and its microRNA-205 target results in enhanced cell
migration and metastasis in prostate cancer. Proc Natl Acad Sci
USA. 109:15312–15317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Adachi R, Horiuchi S, Sakurazawa Y,
Hasegawa T, Sato K and Sakamaki T: ErbB2 down-regulates
microRNA-205 in breast cancer. Biochem Biophys Res Commun.
411:804–808. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Bhatnagar N, Li X, Padi SK, Zhang Q, Tang
MS and Guo B: Downregulation of miR-205 and miR-31 confers
resistance to chemotherapy-induced apoptosis in prostate cancer
cells. Cell Death Dis. 1:e1052010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Fleischmann A, Huland H, Mirlacher M, et
al: Prognostic relevance of Bcl-2 overexpression in surgically
treated prostate cancer is not caused by increased copy number or
translocation of the gene. Prostate. 72:991–997. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Cho IC, Chung HS, Cho KS, et al: Bcl-2 as
a predictive factor for biochemical recurrence after radical
prostatectomy: an interim analysis. Cancer Res Treat. 42:157–162.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Schaefer A, Jung M, Miller K, et al:
Suitable reference genes for relative quantification of miRNA
expression in prostate cancer. Exp Mol Med. 42:749–758. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Revelos K, Petraki C, Gregorakis A,
Scorilas A, Papanastasiou P and Koutsilieris M: Immunohistochemical
expression of Bcl2 is an independent predictor of
time-to-biochemical failure in patients with clinically localized
prostate cancer following radical prostatectomy. Anticancer Res.
25:3123–3133. 2005.
|
|
25.
|
Zuker M: Mfold web server for nucleic acid
folding and hybridization prediction. Nucleic Acids Res.
31:3406–3415. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Martin MM, Buckenberger JA, Jiang J, et
al: The human angiotensin II type 1 receptor +1166 A/C polymorphism
attenuates microrna-155 binding. J Biol Chem. 282:24262–24269.
2007.
|
|
27.
|
Grimson A, Farh KK, Johnston WK,
Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Tarasov V, Jung P, Verdoodt B, et al:
Differential regulation of microRNAs by p53 revealed by massively
parallel sequencing: miR-34a is a p53 target that induces apoptosis
and G1-arrest. Cell Cycle. 6:1586–1593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Shen Y, Iqbal J, Huang JZ, Zhou G and Chan
WC: BCL2 protein expression parallels its mRNA level in normal and
malignant B cells. Blood. 104:2936–2939. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Carvalho JR, Filipe L, Costa VL, et al:
Detailed analysis of expression and promoter methylation status of
apoptosis-related genes in prostate cancer. Apoptosis. 15:956–965.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Gandellini P, Folini M, Longoni N, et al:
miR-205 Exerts tumor-suppressive functions in human prostate
through down-regulation of protein kinase C epsilon. Cancer Res.
69:2287–2295. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Wright JL SC, Lin DW, Kolb S, et al:
Prostate cancer specific mortality and Gleason 7 disease
differences in prostate cancer outcomes between cases with Gleason
4+3 and Gleason 3+4 tumors in a population based cohort. J Urol.
182:2702–2707. 2009.
|
|
33.
|
Greene SB, Gunaratne PH, Hammond SM and
Rosen JM: A putative role for microRNA-205 in mammary epithelial
cell progenitors. J Cell Sci. 123:606–618. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Yoshino T, Shiina H, Urakami S, et al:
Bcl-2 expression as a predictive marker of hormone-refractory
prostate cancer treated with taxane-based chemotherapy. Clin Cancer
Res. 12:6116–6124. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Colombel M, Symmans F, Gil S, et al:
Detection of the apoptosis-suppressing oncoprotein bc1-2 in
hormone-refractory human prostate cancers. Am J Pathol.
143:390–400. 1993.PubMed/NCBI
|
|
36.
|
McDonnell TJ, Troncoso P, Brisbay SM, et
al: Expression of the protooncogene bcl-2 in the prostate and its
association with emergence of androgen-independent prostate cancer.
Cancer Res. 52:6940–6944. 1992.PubMed/NCBI
|
|
37.
|
Cimmino A, Calin GA, Fabbri M, et al:
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Hagman Z, Larne O, Edsjo A, et al: miR-34c
is down regulated in prostate cancer and exerts tumor suppressive
functions. Int J Cancer. 127:2768–2776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Cole KA, Attiyeh EF, Mosse YP, et al: A
functional screen identifies miR-34a as a candidate neuroblastoma
tumor suppressor gene. Mol Cancer Res. 6:735–742. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Cho NY, Kim BH, Choi M, et al:
Hypermethylation of CpG island loci and hypomethylation of LINE-1
and Alu repeats in prostate adenocarcinoma and their relationship
to clinicopathological features. J Pathol. 211:269–277. 2007.
View Article : Google Scholar : PubMed/NCBI
|
